Latest Benign Neoplasms News
SpringWorks Therapeutics Reports First Quarter 2024
– Achieved $21.0 million in OGSIVEO® (nirogacestat) net product revenue in the…
SpringWorks Therapeutics Reports First Quarter 2024
– Achieved $21.0 million in OGSIVEO® (nirogacestat) net product revenue in the…
SpringWorks Therapeutics Announces Abstracts Accepted for
– Results from Phase 2b ReNeu trial of mirdametinib in NF1-PN accepted…
SpringWorks Therapeutics Announces Abstracts Accepted for Presentation at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting
– Results from Phase 2b ReNeu trial of mirdametinib in NF1-PN accepted…
Rosie O’Donnell: I’m married, selling art on eBay
LOS ANGELES (AP) — Rosie O’Donnell has announced that she married her…
Nirogacestat Linked With Improved Functional Status in Patients With Desmoid Tumors
Nirogacestat (Ogsiveo) was associated with significant and clinically meaningful improvements in functional…
SpringWorks Therapeutics Announces European Medicines
STAMFORD, Conn., Feb. 29, 2024 (GLOBE NEWSWIRE) -- SpringWorks Therapeutics, Inc. (Nasdaq:…
Psychosocial Impact and Pain Management for Desmoid Tumors
This is a video synopsis/summary of a Peer Exchange involving Ryan Haumschild,…
Turning to Patients to Help Drive Rare Disease Drug Development
Pictured: A physician stands with a family against a drug development background/Nicole…